Osteoporosis
📧 Sign up to get email alerts when something new happens for Osteoporosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-02-10Clinical Trial Update: Study of a Bone Assessment Technique, Bone Mineral Analyser, Concerning the Prediction of Improvement in Bone Status After an Infusion of Zoledronic Acid in Osteoporotic Women [NA]
This document notes the withdrawal of a clinical trial evaluating a bone assessment technique to predict improvement in bone status after zo…
-
CLINICAL_TRIALS withdrawal · 2025-11-20Clinical Trial Update: Comparison of the Effectiveness of a Web Fracture Liaison Service (e_FLS) to Fracture Liaison Services in France: the evAB Study (evAB)
The evAB study comparing a web fracture liaison service (e_FLS) to standard fracture liaison services in France has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-05-25Clinical Trial Update: Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis [NA]
A clinical trial evaluating a novel resistance exercise for individuals with osteoporosis/osteopenia has been withdrawn from the registry.
-
CLINICAL_TRIALS withdrawal · 2025-05-11Clinical Trial Update: Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia® [Phase 3]
A Phase 3 trial comparing MAB-22 with Prolia (denosumab) for osteoporosis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-04-08Clinical Trial Update: Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Osteoporosis [Phase 1]
Phase 1 trial evaluating the safety of intravenous infusion of cultured allogeneic umbilical cord-derived mesenchymal stem cells for osteopo…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2024-12-24Clinical Trial Update: Exercise and Posture in Individuals with Osteoporosis [NA]
Clinical trial update announcing the withdrawal of a study on exercise and posture interventions for osteoporosis.
-
EMA withdrawal · 2020-09-28EMA Application withdrawn: Sondelbay (teriparatide) — Accord Healthcare S.L.U.
The EMA has withdrawn the application for Sondelbay (teriparatide) by Accord Healthcare S.L.U. for osteoporosis.
-
EMA withdrawal · 2020-05-19EMA Withdrawn: Osseor (strontium ranelate) — Les Laboratoires Servier
The EMA has withdrawn Osseor (strontium ranelate) from the market.
-
EMA withdrawal · 2020-05-15EMA Withdrawn: Protelos (strontium ranelate) — Les Laboratoires Servier
The EMA withdrew Protelos (strontium ranelate) from the market for osteoporosis, postmenopausal indications.
-
CLINICAL_TRIALS withdrawal · 2019-03-13Clinical Trial Update: Study Of The Efficacy And Security Of Ibandronate For Osteoporosis Treatment In A HIV-Infected Patients Cohort [Phase 4]
A Phase 4 trial evaluating ibandronate for osteoporosis in HIV-infected patients was withdrawn.
-
EMA withdrawal · 2019-02-14EMA Refused: Eladynos (abaloparatide) — Radius Health Ireland Ltd
The EMA refused the marketing authorization for Eladynos (abaloparatide) for osteoporosis.
-
EMA withdrawal · 2018-12-12EMA Withdrawn: Zoledronic acid Teva Pharma (zoledronic acid) — Teva B.V.
EMA withdrew zoledronic acid Teva Pharma (zoledronic acid) from the market in 2018 for indications including osteoporosis, osteitis deforman…
-
CLINICAL_TRIALS withdrawal · 2017-07-18Clinical Trial Update: The Effects of Inhaled Glucocorticoids on the Postmenopausal Skeleton [Phase 4]
A Phase 4 trial investigating the effects of inhaled glucocorticoids on the postmenopausal skeleton for osteoporosis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-05-16Clinical Trial Update: Provincial Roll-Out Bone Health Strategy [NA]
A clinical trial evaluating a provincial bone health strategy for osteoporosis has been withdrawn.
-
EMA withdrawal · 2017-02-02EMA Application withdrawn: Alendronic Acid / Colecalciferol Mylan (alendronate sodium trihydrate;colecalciferol) — Mylan S.A.S.
The EMA withdrew the application for Alendronic Acid / Colecalciferol Mylan (alendronate sodium trihydrate; colecalciferol) for osteoporosis…
-
CLINICAL_TRIALS withdrawal · 2016-12-05Clinical Trial Update: Evolution of Bone Mineral Density (BMD) in Patients With Lymphoma Undergoing Chemotherapy [Phase 4]
Phase 4 clinical trial assessing changes in bone mineral density in lymphoma patients undergoing chemotherapy has been withdrawn. The study …
-
EMA withdrawal · 2016-08-08EMA Withdrawn: Zoledronic acid Teva Generics (zoledronic acid monohydrate) — Teva Generics B.V
Withdrawn EMA entry for zoledronic acid Teva Generics (zoledronic acid monohydrate) with therapeutic use in osteoporosis and osteitis deform…
-
CLINICAL_TRIALS withdrawal · 2016-01-05Clinical Trial Update: Development of Non-invasive Method for Quantifying Vitamin D Levels in the Body Using Spectroscopy
A clinical trial evaluating a non-invasive spectroscopy method to quantify vitamin D levels for osteoporosis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-09-17Clinical Trial Update: Teriparatide for Fracture Repair in Humans [Phase 3]
A Phase 3 trial evaluating teriparatide for fracture repair in patients with osteoporosis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-08-27Clinical Trial Update: Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050) [Phase 3]
The Phase 3 trial MK-0822-050 evaluating odanacatib in postmenopausal osteoporosis previously treated with alendronate has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-03-05Clinical Trial Update: Primary Hyperparathyroidism (PHPT): Early Effect of Vitamin D [Phase 2, Phase 3]
A Phase 2/3 clinical trial investigating the early effect of Vitamin D in primary hyperparathyroidism has been withdrawn. The study relates …
-
CLINICAL_TRIALS withdrawal · 2014-12-05Clinical Trial Update: One Week Comparison Study of PTH and PTHrP Infusions [Phase 1]
A Phase 1 trial evaluating infusions of parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) for osteoporosis and relat…
-
CLINICAL_TRIALS withdrawal · 2014-09-05Clinical Trial Update: "PTHrP(1-36) IV Dose Escalation Study" [Phase 1]
A Phase 1 trial evaluating intravenous PTHrP(1-36) dose escalation for osteoporosis was withdrawn.
-
EMA withdrawal · 2014-07-02EMA Withdrawn: Preotact (parathyroid hormone (rDNA)) — NPS Pharma Holdings Limited
EMA has withdrawn Preotact (parathyroid hormone rDNA) from the market.
-
EMA withdrawal · 2013-05-13EMA Withdrawn: Bondenza (previously Ibandronic Acid Roche) (ibandronic acid) — Roche Registration Ltd.
The EMA indicates that Bondenza (ibandronic acid) has been withdrawn from the market.